Endocrine Abstracts

Introduction and aim: Cabergoline, a long-lasting dopamine-agonist, is generally considered to be the safety drug for the treatment of prolactinoma. But, use of long time and high dose cabergoline may be a cause of cardiac valvulopathy in patient with prolactinoma. In present study, we aim to determine serum N-terminal probrain natriuretic peptide levels in patients with prolactinoma who were treated with cabergoline.Materials and methods: Thirty patient...

Introduction and aim: Mean platelet volume (MPV) is a new important indicator of platelet activity in atherosclerosis. Elevated MPV is associated with the presence of more metabolically active platelets. The aim of our study is to evaluate whether change of MPV value is associated with cabergoline treatment in patients with prolactinoma.Materials and methods: Thirty patients with prolactinoma (mean age 33.4±8.5 years and body mass index (BMI): 28.1&...